Replies to post #215146 on Biotech Values

[DewDiligence]

Many biotech stocks are moving up sharply on rather inconsequential press releases, which is probably not a good sign for the sector.

SGMO's PR today is another instance (https://finance.yahoo.com/news/sangamo-announces-treatment-first-patient-061000739.html ).

[DewDiligence]

WVE inks CNS drug-discovery collaboration with Takeda—stock falls:

https://finance.yahoo.com/news/wave-life-sciences-takeda-form-120000869.html

Under terms of the two-component agreement, Takeda will make an initial payment of $110 million to Wave and purchase $60 million of Wave’s ordinary shares at $54.70 per share. Takeda will also fund at least $60 million of Wave research over a four-year period to advance multiple preclinical targets selected by and licensed to Takeda.

[DewDiligence]

WVE -16% on slow enrollment:

https://finance.yahoo.com/news/wave-life-sciences-provides-timing-110000042.html

[DewDiligence]

WVE -64%/PM on discontinuation of Suvodirsen program:

https://finance.yahoo.com/news/wave-life-sciences-announces-discontinuation-120010965.html

Wave Life Sciences…today announced its decision to discontinue development of suvodirsen for patients with Duchenne muscular dystrophy (DMD) who have mutations amenable to exon 51 skipping, based on its interim analysis of the Phase 1 open-label extension (OLE) study. The results showed no change from baseline in dystrophin expression, as measured by western blot, with either the 3.5 mg/kg or 5 mg/kg doses of suvodirsen. No safety concerns or emerging safety signals were observed.

As a result of this decision, the company is immediately discontinuing the two suvodirsen trials, the OLE study and the Phase 2/3 DYSTANCE 51 trial. Patients will have a final follow-up visit, but no further doses will be administered, and patients will no longer undergo muscle biopsies. In addition, Wave is suspending further development of WVE-N531 for patients with mutations amenable to exon 53 skipping.